Evidence map›Paper›PMID 38004425›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Structural Study of a New MbtI-Inhibitor Complex: Towards an Optimized Model for Structure-Based Drug Discovery.

Matteo Mori, Stefania Villa, Laurent R Chiarelli, Fiorella Meneghetti, Marco Bellinzoni

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Biofabricated AlRSC advances · 2026
    Article
  2. TowardMicroorganisms · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Matteo MoriDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.ORCID 0000-0002-7491-1494
Stefania VillaDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.ORCID 0000-0002-0636-7589
Laurent R ChiarelliDepartment of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Via A. Ferrata 9, 27100 Pavia, Italy.ORCID 0000-0003-0348-9764
Fiorella MeneghettiDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.ORCID 0000-0002-6511-7360
Marco BellinzoniInstitut Pasteur, Université Paris Cité, CNRS UMR3528, Unité de Microbiologie Structurale, F-75015 Paris, France.ORCID 0000-0002-8887-6917
University of Milan · ITCentre National de la Recherche Scientifique · FRUniversity of Pavia · IT

Funding

French National Centre for Scientific Research Institutional FundingInstitut Pasteur Institutional fundingUniversity of Milan Linea B
6 · The paper itself

Abstract

MbtI from

Indexed as

anti-virulence therapyco-crystal structureironMycobacterium tuberculosissalicylate synthasesiderophoretuberculosis

Identifiers

PMID38004425
PMCPMC10675255
OpenAlexW4388288709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.